ERBB2 and inflammatory breast carcinoma: Results of a non-randomized phase I study of ruxolitinib in combination with paclitaxel have recently been presented in abstract form, and clinical activity in patients with HER2-negative metastatic breast cancer has been observed.26 In preclinical models of IBC, ruxolitinib appears to add to the efficacy of taxanes (Peluffo et al., manuscript in preparation), and a prospective trial (TBCRC#039, NCT02876302) testing the combination ruxolitinib with paclitaxel in patients with triple-negative IBC is currently recruiting patients.